Deregulated pricing, low-cost Chinese APIs quadrupled Pakistan’s pharma profits: report
Home Page - Profit by Pakistan Today [Unofficial]
February 17, 2026
Companies benefit from a stable exchange rate, a strong product pipeline, and a 35% drop in Chinese API costs; sector is projected to grow 35% YoY in 2026
The post Deregulated pricing, low-cost Chinese APIs quadrupled Pakistan’s pharma profits: report appeared first on Profit by Pakistan Today.
Discussion in the ATmosphere